Exact Sciences

503 articles about Exact Sciences

• Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients

  12/9/2022

  Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today shared initial clinical validation data for its breast cancer radiation signature, Profile for the Omission of Local Adjuvant Radiotherapy (POLAR), at the 2022 San Antonio Breast Cancer Symposium® (SABCS®).

• Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022

  12/6/2022

   Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that new data presentations supporting the clinical value of its Precision Oncology portfolio will be shared in ten abstracts and three presentations at the 2022 San Antonio Breast Cancer Symposium® (SABCS®).

• Exact Sciences Announces Third Quarter 2022 Results

  11/3/2022

  Exact Sciences Corp. announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021.

• Exact Sciences to participate in November 2022 investor conferences

  11/1/2022

  Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.

• Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting

  10/24/2022

  Exact Sciences Corp. today announced the company will present new data supporting the positive impact of Cologuard® as a colorectal cancer screening tool during the American College of Gastroenterology (ACG) Annual Meeting, being held October 21-26, 2022.

• Exact Sciences schedules third quarter 2022 earnings call

  10/10/2022

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company plans to release its third quarter 2022 financial results after the close of the U.S. financial markets on November 3, 2022.

• Exact Sciences Awards Grants to Federally Qualified Health Centers Focused on Improving Colorectal Cancer Screening of Vulnerable Populations

  9/22/2022

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, awarded $525,000 in grants to eight federally qualified health centers focused on improving colorectal cancer screening rates in vulnerable populations.

• Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress

  9/10/2022

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced data from a multi-cancer early detection biomarker validation study was presented at the European Society for Medical Oncology Congress.

• Exact Sciences to participate in September 2022 investor conference

  9/1/2022

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences to participate in August 2022 investor conference

  8/1/2022

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

  7/8/2022

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, applauds the recently announced Centers for Medicare and Medicaid Services Calendar Year 2023 Physician Fee Schedule proposal, which considers follow-up colonoscopy to an at-home test as a preventive service.

• Exact Sciences schedules second quarter 2022 earnings call

  7/8/2022

  Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company plans to release its second quarter 2022 financial results after the close of the U.S. financial markets on August 2, 2022.

• Ultima Genomics and Exact Sciences enter long-term supply agreement aimed at improving patient access to genomic testing by driving down sequencing costs

  6/21/2022

  Ultima Genomics, Inc. and Exact Sciences Corporation have entered a long-term supply agreement for Ultima's next-generation sequencing technologies.

• Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022

  5/27/2022

  Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and treatment guidance tools will be showcased in nine poster presentations and five e-abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 3-7 in Chicago.

• Exact Sciences to participate in June 2022 investor conferences

  5/27/2022

  Exact Sciences Corp., a leader in advanced cancer diagnostics, announced that company management will participate in the following conferences and invited investors to participate by webcast.

• Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX® GPS™ Test, for the First Time in Localized Prostate Cancer Patients

  5/11/2022

  Exact Sciences Corp. announced the American Urological Association updated their guidelines to include genomic assays, such as the Oncotype DX Genomic Prostate Score® test, when treating men with localized prostate cancer.

• Exact Sciences to participate in May 2022 investor conference

  5/2/2022

  Exact Sciences Corp., a leader in advanced cancer diagnostics, announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences Announces First Quarter 2022 Results

  4/26/2022

  Exact Sciences Corp., a leader in advanced cancer diagnostics, announced that the company generated revenue of $486.6 million for the first quarter ended March 31, 2022, compared to $402.1 million for the same period of 2021.

• Exact Sciences schedules first quarter 2022 earnings call

  4/8/2022

  Exact Sciences Corp., a leader in advanced cancer diagnostics, announced that the company plans to release its first quarter 2022 financial results after the close of the U.S. financial markets on April 26, 2022.

• Exact Sciences to participate in March 2022 investor conferences

  2/28/2022

  Exact Sciences Corp., a leader in advanced cancer diagnostics, announced that company management will participate in the following conferences and invited investors to participate by webcast.